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Abstract
Elongation of a poly-glutamine (polyQ) stretch in huntingtin protein (Htt) is linked to 
Huntington’s disease (HD) pathogenesis. The mutation in Htt correlates with neuronal dysfunction 
in the striatum and cerebral cortex, and eventually leads to neuronal cell death. The exact 
mechanisms of the injurious effect of mutant Htt (mHtt) on neurons are not completely 
understood, but might include aberrant gene transcription, defective autophagy, abnormal 
mitochondrial biogenesis, anomalous mitochondrial dynamics and trafficking. In addition, 
deficiency in oxidative metabolism and defects in mitochondrial Ca2+ handling are considered 
essential contributing factors to neuronal dysfunction in HD and, consequently, in HD 
pathogenesis. Since the discovery of the mutation in Htt, the questions whether mHtt affects 
oxidative metabolism and mitochondrial Ca2+ handling and if it does, what mechanisms could be 
involved, were in focus of numerous investigations. However, despite significant research efforts, 
the detrimental effect of mHtt and the mechanisms by which mHtt might impair oxidative 
metabolism and mitochondrial Ca2+ handling remain elusive. In this paper, I will briefly review 
studies aimed at clarifying the consequences of mHtt interaction with mitochondria and discuss 
experimental results supporting or arguing against the mHtt effects on oxidative metabolism and 
mitochondrial Ca2+ handling.
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Huntington’s disease (HD) is a neurodegenerative disorder that belongs to the family of 
polyglutamine (polyQ) diseases [1] and manifests in motor, cognitive, psychiatric, and 
behavioral abnormalities [2]. In 1993, a mutation in huntingtin (Htt), a 350 kDa cytosolic 
protein that is ubiquitously expressed in various tissues was found and linked to HD 
pathogenesis [3]. In healthy individuals Htt contains up to 35 glutamines in a polyQ stretch 
near the N-terminus. The mutation in exon 1 of huntingtin gene leads to increased number of 
CAG repeats that results in elongation of polyQ stretch in Htt beyond 35Qs with 40 or more 
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Qs leading to HD with full penetrance [4]. The elongated polyQ stretch in Htt correlates 
with neuronal dysfunction in the striatum and cerebral cortex, and eventually results in 
neuronal loss [5]. The precise mechanisms of the detrimental effect of mutant Htt (mHtt) on 
neurons are not clear, but may include aberrant gene transcription [6], defective autophagy 
[7] as well as abnormal mitochondrial biogenesis [8], mitochondrial dynamics [9,10,11], and 
trafficking [8,12]. In addition, bioenergetic deficiency and mitochondrial Ca2+ handling 
defects are considered to be important contributing factors to neuronal dysfunction in HD 
[13,14]. Since the discovery of the Htt mutation, numerous studies have been conducted to 
elucidate the mHtt effect on oxidative metabolism and mitochondrial Ca2+ handling. 
However, despite significant efforts, the question whether mHtt impairs mitochondrial 
functions remains controversial and not completely understood. In this paper, I briefly 
review experimental data that demonstrate mHtt effects or the lack thereof on oxidative 
metabolism and mitochondrial Ca2+ handling highlighting existing contradictions.
OXIDATIVE MEATBOLISM
In early papers concerning HD-associated alterations in mitochondrial bioenergetics, even 
before discovery of mutation in Htt, investigators reported some defects in mitochondrial 
respiratory activity. In postmortem brain tissues from HD patients, decreased respiratory 
activity of caudate mitochondria was found [15], and defects in mitochondrial Complexes II, 
III, and IV were described [16,17]. However, it was not obvious whether these respiratory 
defects contributed to HD pathogenesis or they were a result of the late stage of HD 
pathology. To resolve this issue, various experimental models of HD have been developed 
and utilized in search of a mechanistic link between mutation in Htt and HD pathology. The 
effects of mHtt on oxidative metabolism have been examined with polyQ-GST fusion 
proteins as surrogates for mHtt [18,19], with cell models expressing mHtt [20] as well as 
with numerous HD rodent models that express full-length or fragments of endogenous or 
human mHtt with different length of polyQ stretch [21,22].
The polyQ-GST fusion proteins were generated and tested in experiments with isolated 
mitochondria from wild-type (WT) animals. In experiments with Q62-GST fusion protein 
applied to liver mitochondria isolated from WT mice, investigators found a slight inhibition 
of ADP-stimulated respiration, but no inhibition of respiratory complexes, ATP synthase, 
and adenine nucleotide translocase [18]. Another mHtt substitute, GST-51Q exon 1 fusion 
protein, resulted in depolarization in isolated rat brain cortical mitochondria accompanied by 
a significant increase in oxygen consumption by the organelles, suggesting mitochondrial 
uncoupling but not inhibition of mitochondrial respiratory complexes [19]. Interestingly, in 
this study GST-20 exon 1 fusion protein with an unexpanded polyQ stretch produced similar 
effects, arguing against the role of an expanded polyQ stretch in the observed mitochondrial 
defects.
The opportunities to investigate the effects of mHtt on cell physiology and biochemistry 
were significantly expanded with the advent of conditionally immortalized, mutant 
STHdhQ111/Q111 striatal neuronal progenitor cells [20]. Using these cells, Milakovic and 
Johnson, although observed reduced respiration and ATP production, found no difference in 
activities of mitochondrial Complex I-IV in mutant STHdhQ111/Q111 cells compared with 
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STHdhQ7/Q7 cells [23]. The authors concluded that mHtt may impair mitochondrial 
bioenergetics via different mechanisms that do not directly affect respiratory Complexes. In 
line with this conclusion, Seong et al. found lower cellular ATP in STHdhQ111/Q111 cells 
compared with STHdhQ7/Q7 cells [24]. The authors found inhibition of ADP uptake by 
mitochondria from mutant cells; however, activity of adenine nucleotide translocase that 
catalyzes ADP/ATP exchange across the inner membrane remained unchanged. 
Mitochondrial membrane potential was decreased whereas intracellular Ca2+ was elevated in 
mutant cells. The elevated intracellular Ca2+ was proposed to be responsible for inhibition of 
ADP transport into mitochondria. Indeed, inhibition of Ca2+ influx into STHdhQ111/Q111 
cells with EGTA in the bath solution or NMDA receptor antagonist MK801 significantly 
increased ATP/ADP ratio in these cells, suggesting improvement in ADP translocation into 
mitochondria [24]. Recently, in experiments with STHdhQ111/Q111 cells, Siddiqui et al. 
found slightly reduced maximal respiratory activity without any difference in basal 
respiration [25]. The authors obtained a similar result with primary cultures of HD diploid 
skin fibroblasts. Consistent with these findings, in experiments with hetero- and 
homozygous STHdhQ111/Q7 and STHdhQ111/Q111 striatal neuronal progenitor cells, Napoli 
et al. found deficient oxidative phosphorylation and decreased Complex I and IV activities 
as well as a decrease in F0F1-ATPase activity [26]. It has to be noted, however, that 
immortalized neuronal progenitor cells may differ functionally and morphologically from 
primary neurons and, therefore, mHtt effects on oxidative metabolism in these cells should 
be taken cautiously, especially, bearing in mind negative results produced in numerous 
experiments with primary neurons, brain slices, and whole HD animals.
In addition to experiments with polyQ-GST fusion proteins and immortalized neuronal 
progenitor cells, experiments with isolated mitochondria and cells in culture derived from 
HD animal models provided important information about the possible effects of mHtt on 
oxidative metabolism. Tabrizi et al., using biochemical assays, found a significant decrease 
in activities of Complex IV and aconitase in the striatum of R6/2 mice [27]. In line with 
these findings, Bae et al., using the same methodology, reported decreased activity of 
Complex IV in striatum of N171-82Q transgenic mice [28]. Later, Kim et al. found 
significant reduction in States 3 and 4 respiration of succinate-fueled striatal mitochondria 
from pre-symptomatic transgenic D9-N171-98Q mice, also known as DE5 mice, compared 
with their age-matched controls, suggesting Complex II impairment [29]. On the other hand, 
Complex I and IV activities as well as activity of ATP synthase, were not altered in the 
striatum of young and old DE5 mice compared with WT littermates. Interestingly, succinate-
supported respiration in States 3 and 4 as well as maximal FCCP-stimulated respiration were 
found to be increased in symptomatic DE5 mice compared with presymptomatic animals 
[29]. Damiano et al. also reported defects in respiration of mitochondria isolated from 
forebrains of N171-82Q transgenic mice [30]. With malate/glutamate (Complex I substrates) 
or succinate (Complex II substrate) supplemented with glutamate, ADP-stimulated 
respiration of mitochondria from 2-3 month old N171-82Q transgenic mice was lower 
compared to respiration of mitochondria from control N171-Q18 mice. Recently, Aidt et al. 
measured respiration of striatum homogenates from 12-week old R6/2 mice and found a 
slight but statistically significant decrease in Complex II and Complex IV flux control ratios 
defined as respiratory rates normalized to the maximal uncoupled respiration [31]. The 
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authors interpreted these data as an indication of respiratory impairment in striatal 
mitochondria of R6/2 mice. However, how mHtt, a 350 kDa cytosolic protein that binds to 
the outer mitochondrial membrane, but cannot cross it [32], impairs the respiratory chain in 
the inner mitochondrial membrane remains not completely understood. One possibility is 
that mHtt might decrease expression and mitochondrial import of proteins, involved in 
oxidative metabolism. Indeed, loss of Complex II activity was found in the postmortem 
striatum of HD patients and associated with a decreased expression of two subunits of 
Complex II, iron-sulfur subunit Ip (30 kDa) and FAD subunit Fp (70 kDa) [33]. Similarly, 
Damiano et al. demonstrated preferential loss of Complex II in mitochondria isolated from 
forebrains of N171-82Q transgenic mice [30]. Recently, Yano et al. reported mHtt-mediated 
inhibition of mitochondrial protein import [34]. On the other hand, no decrease in Complex 
II levels (judged by the levels of 30 and 70 kDa subunits of Complex II) was found in brain 
mitochondria isolated from Hdh150Q knock-in mice [35] and in mitochondria of 
STHdhQ111/Q111 cells [23]. Possible alterations in oxidative metabolism could decrease ATP 
production in cells, expressing mHtt. Lim et al. reported a significant decrease in ATP level 
in cortex of R6/1 mice compared with WT control [36]. Although in HD striatum is 
considered the most vulnerable region of the brain [5], a decrease of ATP in striatum was 
much less pronounced and was not statistically significant [36].
In addition to studies, reporting mHtt-induced impairment of oxidative metabolism, there are 
numerous studies that demonstrate the lack thereof. Trushina et al. discovered a reduction in 
mitochondrial motility due to sequestration of trafficking motors components by mHtt 
aggregates, but did not find signs of mitochondrial dysfunction in striatal neurons derived 
from YAC72 mice [12]. Mitochondrial morphology was not altered in these neurons and the 
levels of ATP and lactate (an indicator of glycolytic activity) were similar in neurons from 
WT and YAC72 mice. Olah et al. reported that the activities of Complexes I-IV in brain 
mitochondria from 20-week old transgenic N171-82Q mice were not decreased compared 
with mitochondria from WT animals [37]. Interestingly, the authors found that ATP levels in 
the homogenate of the posterior brain regions of N171-82Q mice were significantly higher 
than in brains from WT mice. In addition, the authors noticed an increased glycolytic rate in 
cytosolic extracts from brain tissue of N171-82Q mice [37]. Based on these observations, the 
authors concluded that expression of the N-terminal fragment of mHtt is not accompanied 
by decreased activity of the mitochondrial respiratory chain or decline in glycolytic rate. 
Consistent with this, Guidetti et al. did not find any changes in mitochondrial electron 
transport through Complexes I-IV in the striatum and cerebral cortex of HD48 and HD89 
mice, expressing full-length mHtt with either 48 or 89 Qs in polyQ stretches, compared with 
WT animals [38]. Moreover, these investigators failed to find changes in the activity of 
Complexes I-IV in the neostriatum and cerebral cortex in pre-symptomatic and pathological 
Grade 1 HD cases. Oliveira et al. reported that respiration of cultured striatal neurons 
derived from heterozygous knock-in Hdh150/+ mice and their WT littermates was similar 
[39]. Later, Gouarne et al. measured respiration of cultured striatal neurons from 
heterozygous transgenic BACHD rats and found no difference compared with WT neurons, 
when cells were incubated in the presence of 25 mM glucose and 1 mM pyruvate [40]. 
However, when neurons were incubated in low glucose (2.5 mM) medium, the authors 
observed a modest decrease in maximal, FCCP-stimulated respiration of mHtt expressing 
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cells. Interestingly, this difference between mutant and WT cells was observed only with 
striatal but not cortical neurons. The authors proposed that mHtt expression results in a 
dysfunction in glycolysis that might precede defects in mitochondrial respiration [40]. Yano 
et al. reported that respiration of synaptic and non-synaptic mitochondria from forebrains of 
pre-symptomatic and mid-stage disease R6/2 mice (the authors used two distinct R6/2 
strains: 150 CAG R6/2 and 195CAG R6/2) was not different from that of mitochondria from 
WT littermates [34]. Consistent with this, in a recent study with neurons and astrocytes from 
BACHD mice, Boussicault et al. found no evidence for direct effect of mHtt with 97 Qs on 
oxidative metabolism in these cells in vitro [41]. In this study, mHtt did not affect the 
glycolytic rate in single cells as measured by FRET and did not decrease mitochondrial 
membrane potential in neurons assessed with Rhodamine 123. Taken together, these data 
obtained with isolated mitochondria and cells in culture argue against mHtt-induced 
impairment of oxidative metabolism in animal models of HD.
In addition to isolated mitochondria and cells in culture, experiments with animal brain 
slices and whole animals in vivo provided further insights into the possible effect of mHtt on 
respiratory activity. Weydt et al. reported that oxygen consumption measured by indirect 
calorimetry of the whole animals was slightly increased in transgenic HD N171-82Q mice at 
baseline, especially during fasting [42]. The oxygen consumption rates (OCRs) in brain 
slices from 11-week-old, pre-symptomatic N171-82Q mice incubated with 20 mM glucose 
were similar. However, when brain slices were incubated with 5 mM lactate and 1 mM 
pyruvate, OCRs for HD slices were significantly lower [42]. Thus, the ability of lactate to be 
converted to pyruvate and subsequently undergo oxidative metabolism in the citric acid 
cycle appeared to be impaired in brains of N171-82Q mice. At the same time, respiration of 
brain slices fueled by succinate was normal, indicating the lack of impairment of the 
respiratory chain. Goodman et al. reported that 8-week-old R6/2 mice had oxygen 
consumption, energy expenditure, and respiratory exchange ratio (RER, CO2 release rate/
oxygen consumption rate) similar to WT animals [43]. With 14-week-old R6/2 mice, the 
authors found significantly increased oxygen consumption and energy expenditure, while 
RER was not significantly different. Van der Burg et al. found elevated oxygen consumption 
in 6- to 12-week-old R6/2 mice compared with WT littermates [44]. In elegant in vivo 
experiments with magnetic resonance spectroscopy (31P MRS), Tkac et al. found no 
significant change in ATP concentration in the brain of knock-in Q111 mice [45]. ADP 
concentration and a relative rate of ATP synthase were increased in brain of Q111 mice at 6 
weeks, but returned to nearly normal level at 13 weeks. In R6/2 mice, however, these 
parameters remained normal. The authors proposed that brain energy homeostasis in these 
HD mouse models is maintained from early ages until the pathological symptoms become 
apparent. Overall, these data argue against an overt inhibitory effect of mHtt on oxidative 
energy metabolism.
The experiments with cell and animal models generate important information about HD, but 
only studies with human tissues and HD patients provide an ultimate test to the hypotheses 
generated in animal studies. Severe reduction in the activity of mitochondrial respiratory 
chain Complexes was found in caudate/putamen from human post-mortem brain tissue, 
suggesting that these abnormalities may underlie HD pathology [15,16,17]. However, in 
vivo measurements of oxygen consumption and glucose metabolism with positron emission 
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tomography in early-stage HD patients demonstrated that, while glucose consumption was 
somewhat reduced in striatum, its respiratory capacity was not significantly altered [46]. 
Consistent with this, the mid-stage HD patients do not show energy imbalance in vivo 
compared to age-matched healthy individuals as judged by indirect calorimetry in a human 
respiratory chamber [47]. Turner et al. studied the respiratory chain function in skeletal 
muscle biopsies from HD patients and also failed to find a significant difference in the 
activities of Complexes I-IV compared with age-matched controls [48]. Powers et al. 
investigated platelet mitochondrial citrate synthase and Complex I and I/III activities in HD 
patients and found no difference compared with healthy controls, whereas striatal volume 
was already significantly reduced in patients with HD [49]. In another study, using positron 
emission tomography applied to live HD patients with manifested striatal atrophy, Powers et 
al. obtained data inconsistent with a defect in mitochondrial oxidative metabolism due to 
reduced activity of the mitochondrial respiratory chain [46]. Because HD pathology was 
already manifested by striatal atrophy, the authors concluded that a deficit in energy 
production due to impairment of mitochondrial respiratory chain is not important for the 
mechanism of neuronal death in early HD.
Thus, the existing literature supports two different views on the interaction of mHtt with 
oxidative metabolism system. One group of investigators reports detrimental effects of mHtt 
on oxidative metabolism, whereas another group does not find evidence for such effects. 
This contradiction limits our understanding of HD pathogenesis and impedes the 
development of new treatment approaches for HD. Consequently, this contradiction has to be 
resolved in order to provide explicit answers to the questions of whether mHtt results in 
defects in oxidative metabolism and whether these defects contribute to HD pathogenesis 
and therefore represent a valid target for the development of effective HD therapies.
MITOCHONDRIAL CALCIUM HANDLING
One of the main hypotheses regarding HD pathology postulates that expression of mHtt 
results in defects in Ca2+ signaling in neurons [50] most likely due to alterations in activity 
of NMDA-subtype of ionotropic glutamate receptors [51], abnormalities in IP3 receptor 
function [52], and aberrations in mitochondrial Ca2+ handling [14]. The inner mitochondrial 
membrane has a Ca2+ channel [53,54], historically called the Ca2+ uniporter [55], that 
mediates Ca2+ influx into the mitochondrial matrix driven by large membrane potential 
negative inside of mitochondria. The magnitude of mitochondrial Ca2+ uptake capacity is 
restricted by the sensitivity of mitochondria to the damaging effect of Ca2+, manifested in an 
induction of the mitochondrial permeability transition pore (PTP) [56].
Several studies demonstrated mHtt-induced defects in mitochondrial Ca2+ uptake (defects in 
mitochondrial Ca2+ handling). An early paper by Panov et al. reported bioenergetic 
abnormalities and a reduction in Ca2+ uptake capacity by mitochondria isolated from cells 
and tissues expressing mHtt [14]. Mitochondria from lymphoblasts of patients with HD as 
well as brain nonsynaptic mitochondria from pathological YAC72 mice had a diminished 
membrane potential and were depolarized at smaller Ca2+ loads compared with 
mitochondria from healthy YAC18 mice. These defects appeared to be upstream of the onset 
of pathological or behavioral abnormalities and could be replicated by a fusion protein GST-
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Q62 containing expanded polyQ repeat. It is known that Ca2+ uptake capacity could be 
increased by a combination of ADP and cyclosporin A (CsA), efficient inhibitors of the PTP 
[57,56]. However, Panov et al. reported that the Ca2+ handling defect persisted even in the 
presence of these PTP inhibitors [14]. Thus, the mechanism of the mitochondrial Ca2+ 
handling defect was not clarified in this study, but based on the fact that ADP and CsA failed 
to eliminate the difference between mitochondria from mutant and WT animals, PTP 
involvement could be excluded. Intriguingly, the effect of mHtt on mitochondrial Ca2+ 
uptake capacity appeared to be elusive, and in the next study Panov et al. found that “the 
defect in Ca2+ handling in brain mitochondria was consistently observed only if brain 
mitochondria were isolated without BSA” [58]. The authors proposed that BSA could 
replace mHtt in its binding sites on mitochondria, but did not provide experimental evidence 
supporting this hypothesis.
Soon after that, Choo et al. showed that liver mitochondria from homozygous knock-in 
Hdh150/150 mice had augmented predisposition to the Ca2+-induced PTP [32]. The authors 
also found that GST-fused N-terminal truncated mHtt (GST-exon1-Q65 or Htt65), 
containing 65 glutamines, and GST-Q62 fusion protein, containing 62 glutamines, 
significantly increased mitochondrial susceptibility to Ca2+-dependent PTP induction. Htt65 
reduced Ca2+ threshold for PTP induction and could directly stimulate Ca2+-dependent PTP 
induction in mouse liver mitochondria [32]. Later, Milakovich et al. showed that in 
mitochondria isolated from conditionally immortalized striatal progenitor cells 
STHdhQ111/Q111, mHtt with 111 glutamines augmented mitochondrial sensitivity to Ca2+-
induced decrease in ADP-activated respiration (State 3) and mitochondrial depolarization 
[59]. In addition, mHtt reduced mitochondrial Ca2+ uptake capacity that could be salvaged 
by a combination of ADP and CsA, the inhibitors of the PTP [57], thus linking PTP 
induction to the mHtt-induced Ca2+ handling defect. In line with this, Lim et al., using the 
same cell lines, demonstrated that mitochondria from the cells had reduced Ca2+ uptake 
capacity due to increased susceptibility to PTP induction [60]. In support of these findings, 
Gizatullina et al. observed increased propensity of skeletal muscle mitochondria from R6/2 
mice to Ca2+-induced PTP compared with mitochondria from WT mice [61]. In the 
following study, Gellerich et al. examined brain mitochondria isolated from transgenic HD 
rats expressing a 727 amino acid fragments of mHtt with a 51Q-stretch [62]. The authors 
found that the mHtt fragments reduced membrane potential stability in response to Ca2+, 
decreased Ca2+ uptake capacity, and diminished Ca2+ threshold for PTP induction.
In addition to isolated mitochondria, neurons in culture were used to study detrimental 
effects of mHtt on Ca2+ signaling and mitochondrial Ca2+ handling. Fernandes et al. 
reported that Ca2+ influx into cells mediated by the NMDA-subtype of ionotropic glutamate 
receptors resulted in augmented mitochondrial depolarization in medium spiny neurons from 
YAC128 mice [63]. This effect was paralleled by reduced clearance of elevated cytosolic 
Ca2+ following NMDA withdrawal. Suppression of the PTP by CsA or bongkrekic acid 
resulted in a decrease in cytosolic Ca2+ and diminished mitochondrial depolarization 
induced by NMDA in neurons from YAC128 mice, but not from WT mice. Based on these 
observations, the authors concluded that mitochondria in medium spiny neurons from 
YAC128 mice have increased susceptibility to PTP induction by Ca2+ [63]. In support of this 
view, Quintanilla et al. found that rat cortical neurons expressing a fragment of mHtt with 
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104 glutamines (Q104-GFP) are more susceptible to Ca2+ stress compared with neurons 
expressing a fragment of Htt with 25 glutamines (Q25-GFP) [64]. The authors also reported 
that mitochondrial defects in mutant STHdhQ111/Q111 cells and cortical neurons expressing 
Q104-GFP were attenuated by CsA, suggesting an important role for PTP in mitochondrial 
injury induced by Ca2+ stress in cells expressing mHtt. Overall, these data suggest that mHtt 
impairs mitochondrial Ca2+ uptake capacity by increasing susceptibility to PTP induction. 
Similar to studies aimed at elucidating mHtt effects on oxidative metabolism, the major 
remaining question is how does mHtt, a 350 kDa cytosolic protein that binds to the outer 
mitochondrial membrane [32], affect mitochondrial Ca2+ handling and increase propensity 
to PTP induction, which are the processes mainly associated with the inner mitochondrial 
membrane.
Despite reported defects in mitochondrial Ca2+ handling, some investigators did not find 
evidence for mHtt-induced mitochondrial Ca2+ handling deficiency and increased propensity 
to PTP induction in the presence of mHtt. In our early study, we did not find an increased 
susceptibility to Ca2+-induced PTP induction in striatal nonsynaptic mitochondria from HD 
mice (Q50, Q92, Q111 and R6/2 mice) compared with mitochondria from WT animals [65]. 
Surprisingly, we found increased resistance to Ca2+ in striatal mitochondria isolated from 
HD mice. In line with our findings, Oliveira et al. demonstrated that nonsynaptic 
mitochondria from R6/2 and YAC128 mice had augmented Ca2+ uptake capacity compared 
with mitochondria from WT mice whereas mitochondria from Hdh150/+ and Hdh150/150 mice 
had similar Ca2+ uptake capacity compared with mitochondria from WT animals [39]. The 
reason for the increased Ca2+ uptake capacity is not clear, but it may reflect compensatory 
adaptation to augmented Ca2+ influx via overactivated NMDA receptors and/or increased 
Ca2+ release from endoplasmic reticulum via abnormally activated IP3 receptors [50]. Both, 
our study [65] and the study by Oliveira et al. [39], suggest that the lack of mHtt-induced 
impairment of mitochondrial Ca2+ handling argues against facilitated PTP induction in the 
presence of mHtt and, consequently, does not support involvement of the PTP in HD 
pathogenesis. Additional evidence for the lack of mitochondrial Ca2+ handling defects came 
from experiments by Chang et al. who transiently exposed cortical neurons expressing N-
terminal fragment of mHtt or full-length mHtt to glutamate and used FCCP-induced 
mitochondrial depolarization to release Ca2+ accumulated in the mitochondrial matrix [66]. 
In these experiments, the authors failed to find significant effect of mHtt on the ability of 
neuronal mitochondria to accumulate Ca2+ following exposure of neurons to excitotoxic 
glutamate. Recently, Wang et al. evoked Ca2+ mobilization in medium spiny neurons by 
stimulating group I metabotropic glutamate receptors and eliciting inositol 1,4,5-
trisphospahe (InsP3) generation. They found significantly higher Ca2+ accumulation in 
mitochondria of neurons from YAC128 mice compared with neurons from WT mice [67]. 
These data argue against mHtt-induced mitochondrial Ca2+ handling defects. However, even 
if these defects exist, their role in HD pathogenesis could be non-essential. Consistent with 
the dispensable role of mitochondrial Ca2+ handling defects in HD pathogenesis, Perry et al. 
demonstrated that R6/2 mice crossed with cyclophilin D-knockout mice (cyclophilin D 
(CyD) is an important regulatory component of the PTP that sensitizes the pore to 
Ca2+ [68,69]) had augmented neuronal mitochondrial Ca2+ uptake capacity without any 
improvement in either behavioral or neuropathological characteristics [70]. The authors 
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reasoned that increased Ca2+ capacity of neuronal mitochondria is not advantageous for 
R6/2 mice. Altogether, these results cast doubt on the ability of mHtt to increase 
susceptibility to PTP induction and to decrease mitochondrial Ca2+ uptake capacity. 
Consequently, these data question the role of mitochondrial Ca2+ handling defects in HD 
pathogenesis. Thus, there are two distinct schools of thought, where one reported mHtt-
induced defects in mitochondrial Ca2+ uptake and increased susceptibility to PTP induction, 
whereas the other did not find evidence for these deleterious alterations associated with 
mHtt. The reason for this discrepancy is not clear, but it could be related to the use of 
different HD models and variations in methodological approaches. One of the major 
remaining problems here is to explain how 350 kDa cytosolic protein that cannot cross the 
outer membrane may affect mitochondrial Ca2+ handling that mainly depends on the 
processes in the inner mitochondrial membrane.
Concluding Remarks
Similar to studies of the effect of mHtt on oxidative metabolism discussed in the first half of 
this paper, the data about the effect mHtt on mitochondrial Ca2+ handling are contradictory. 
One group of investigators finds mHtt induced defects in mitochondrial Ca2+ handling, 
whereas another group does not. The reason for this contradiction is not clear. Consequently, 
additional studies are necessary to resolve this issue, and it seems very likely that a 
collaborative effort involving investigators from the opposite camps might be the best way to 
reconcile the existing contradictions and to firmly establish whether or not mHtt affects 
mitochondrial functions.
It is known that mHtt does not acutely damage neurons. In most cases, the HD patients 
remain asymptomatic until their late 30s and 40s. Different animal models of HD at the early 
ages demonstrate the lack of overt functional and behavioral abnormalities. 
Correspondingly, one of the major challenges in HD studies is to determine detrimental 
mechanisms that produce subtle cumulative effects leading over time to synaptic 
malfunction, neuronal injury, and eventually, to loss of neurons. While the findings 
concerning respiratory defects and Ca2+ handling abnormalities in the mitochondria of HD 
animal models are contradictory, there is a consensus about the presence of mHtt-triggered 
alterations in mitochondrial dynamics (balance of fission and fusion) [71,9,10,11] and 
motility of organelles [12,66,35,8]. Aberrant mitochondrial dynamics may affect 
mitochondrial quality control mechanisms, resulting in an accumulation of dysfunctional 
mitochondria over time. The decreased mitochondrial motility may limit the ability of 
neurons to adequately respond to sudden augmentation of energy demand at distant 
synapses. Although these alterations may not be critical for neuronal function and survival at 
early ages, over time they could produce detrimental changes, contributing to HD 
pathogenesis. Despite compelling evidence indicating aberrant mitochondrial dynamics and 
decreased mitochondrial motility in HD, the detailed mechanisms underlying these 
alterations are not completely understood. Does mHtt interact and affect individual 
components of mitochondrial trafficking machinery? Are there as yet unidentified proteins 
that might interact with mHtt and be involved in alterations of mitochondrial dynamics 
and/or trafficking in HD? Is there a way to mitigate the possible detrimental consequences of 
mHtt interference with mitochondrial dynamics and trafficking? Answering these questions 
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will bring us closer to understanding of the molecular mechanisms contributing to HD 
pathogenesis and may potentially open new avenues for developing novel HD treatments.
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Table 1
Models of Huntington’s disease discussed in this paper.
HD cell or mouse
model
Origin or genetic construct Effects on oxidative metabolism and
mitochondrial Ca2+ handling
Conditionally
immortalized, mutant
STHdhQ111/Q111 striatal
neuronal progenitor
cells [20]
Derived from knock-in
mice with 111 CAG
repeats in endogenous htt
gene
Inhibited respiration, but respiratory
Complexes are not affected [23]
Slightly reduced maximal respiratory
rate, no difference in basal respiration
[25]
Deficient OXPHOS and decreased
Complex I and IV activities [26]
Reduced Ca2+ uptake capacity and
increased propensity to PTP induction
in mitochondria isolated from
STHdhQ111/Q111 cells [59,60]
Transgenic R6/2 mice
[72]
N-terminal fragment of
human htt with 115-150 or
195 CAG repeats
Activities of Complex IV and
aconitase are decreased [27]
Respiratory impairment of
striatal mitochondria [31]
Respiration of synaptic and
nonsynaptic mitochondria is not
affected [34]
Oxygen consumption is not affected in
8 week old mice, but increased in 14-
week-old animals [43]
Increased propensity to Ca2+ -induced
PTP induction in skeletal muscle
mitochondria [61]
Augmented Ca2+ uptake capacity in
brain nonsynaptic mitochondria [39]
Transgenic N171-82Q
mice [73]
N-terminal fragment of
human htt with 82 CAG
repeats
Decreased Complex IV activity [28]
Activities of Complexes I-IV are not
decreased, glycolysis is increased [37]
ADP-stimulated respiration of isolated
brain mitochondria is decreased [30]
Oxygen consumption by whole
animals slightly increased, electron
respiratory chain is not compromised
[42]
Transgenic D9-N171-
98Q mice, also known
as DE5 mice [74]
N-terminal fragment of
human htt with 98 CAG
repeats
Decreased respiration of succinate-
fueled striatal mitochondria;
Complexes I and IV as well as ATP
synthase are not affected [29]
Transgenic HD48 and
HD89 mice [38]
Full-length human htt gene
with 48 or 89 CAG repeats
Complexes I-IV are not affected in the
striatum and cortex [38]
Transgenic YAC72
mice [75]
Full-length human htt gene
with 72 CAG repeats
Diminished mitochondrial membrane
potential, decreased Ca2+ uptake
capacity [14]
Transgenic YAC128
mice [76]
Full-length human htt gene
with 128 CAG repeats
Augmented mitochondrial
depolarization in response to Ca2+ in
medium spiny neurons, increased
susceptibility to PTP induction [63]
Augmented Ca2+ uptake capacity in
brain nonsynaptic mitochondria [39]
Transgenic BACHD
mice [77]
Full-length human htt gene
with 97 mixed CAA-CAG
repeats
No effect of mHtt on oxidative
metabolism in cultured astrocytes and
neurons [41]
Knock-in Q50, Q92,
and Q111 mice [78]
Mouse htt gene with
inserted 50, 92, or 111
CAG repeats in exon 1
No increase in sensitivity to Ca2+-
induced damage in striatal and
cortical nonsynaptic mitochondria [65]
Knock-in Hdh150Q mice [79] Mouse htt gene with
inserted 150 CAG repeats
in exon 1 in a single allele
Respiration of striatal cultured
neurons from Hdh150/+ is not affected
[39]
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HD cell or mouse
model
Origin or genetic construct Effects on oxidative metabolism and
mitochondrial Ca2+ handling
(Hdh150/+) or both alleles
(Hdh150/150)
Liver mitochondria from Hdh150/150
mice have increased propensity to
Ca2+ -induced PTP [32].
No change in Ca2+ uptake capacity in
brain nonsynaptic mitochondria [39]
Transgenic BACHD
rats [80]
Full-length human htt gene
with 97 mixed CAA/CAG
repeats
No difference in respiration of
cultured striatal neurons incubated
with high glucose and pyruvate;
modest decrease in maximal
respiration in the presence of low
glucose; respiration of cortical
neurons is not affected [40]
Transgenic HD rats
[81]
Express 727 amino acids of
the htt51Q gene,
corresponding to 22% of
the full-length gene
Reduced mitochondrial membrane
potential stability in response to Ca2+,
decreased Ca2+ uptake capacity,
increased propensity to PTP induction
[62]
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